Do you want to read an article? Please log in or register.
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer.
Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F
doi: 10.1016/j.cllc.2019.06.012.
RECOMMENDED
Lung Cancer
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer.
De Giglio A, Lamberti G, Facchinetti F, Genova C, Andrini E, Dal Bello MG, Tiseo M, Metro G, Chiari R, Ricciuti B
doi: 10.1016/j.cllc.2020.03.008.
Lung Cancer
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Lancet Respir Med.
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC
RECOMMENDED
Lung Cancer
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
Clin Lung Cancer.
Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, Rossi A, Giannetta L, Sala L, Finocchiaro G, Pizzutilo EG, Carelli S, Agustoni F, Cergnul M, Zonato S, Siena S, Bidoli P, Ferrari D
doi: 10.1016/j.cllc.2020.05.004.
RECOMMENDED
Lung Cancer
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Alexander Meisel, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol.
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
doi: 10.1016/S1470-2045(19)30519-4.
RECOMMENDED
Lung Cancer
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug
Lung Cancer.
Stahel RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes KL, Kohler M, Guckenberger M, Weder W
doi: 10.1016/j.lungcan.2020.05.037.
Lung Cancer
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States
Clin Lung Cancer.
Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A
doi: 10.1016/j.cllc.2020.09.004.
RECOMMENDED
Lung Cancer
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 3
Recommended by
Alexander Meisel, Faculty Member
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, RELAY Study Investigators.
doi: 10.1016/S1470-2045(19)30634-5.
RECOMMENDED
Lung Cancer
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM
doi: 10.1016/j.cllc.2020.07.016.